Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.

This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA(Venetoclax with Homoharringtonine,Etoposide,Cytarabine)regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities. This study includes the induction and consolidation phases of AML treatment.

Trial Details

NCT ID
NCT06328179
Phase
NA
Sponsor
Huai'an First People's Hospital
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Venetoclax 100 mg d1,200 mg d2,400 mg d3-14;
Locations (sample)
  • Huai'an, Jiangsu, China|33.58861,119.01917

Key Eligibility Criteria

  • Age between 18 and 60 years old;Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Expected survival time of at least 3 months.
  • Does not meet any of the following criteria for severe heart, lung, liver, or kidney disease:A) History of congestive heart failure requiring treat…
  • No other significant contraindications to chemotherapy as determined by the physician;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →